Advaxis Initiated with a Buy at Cantor FitzgeraldBy Ryan Adsit
According to TipRanks.com, Goldstein is a 4-star analyst with an average return of 4.0% and a 47.0% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Corvus Pharmaceuticals Inc, and Axsome Therapeutics Inc.
Currently, the analyst consensus on Advaxis is Strong Buy and the average price target is $21.50, representing a 151.2% upside.
In a report issued on November 16, H.C. Wainwright also reiterated a Buy rating on the stock with a $23 price target.
Based on Advaxis’ latest earnings report for the quarter ending July 31, the company posted quarterly revenue of $0 and GAAP net loss of $16.49 million. In comparison, last year the company earned revenue of $0 and had a GAAP net loss of $12.58 million.
Based on the recent corporate insider activity of 68 insiders, corporate insider sentiment is neutral on the stock. Most recently, in December 2014, Adage Capital Partners Gp Llc, a Major Shareholder at ADXS bought 4,454,604 shares.
Advaxis, Inc. is a clinical-stage biotechnology company, which intends to develop immunotherapies for cancer and infectious diseases. The company’s platform technology is designed to generate a comprehensive immune response by serving as its own adjuvant, directing antigen presentation, increasing tumor infiltrating killer T-cells, and decreasing Tregs/MDSCs in the tumor. Advaxis was founded on June 5, 1987 and is headquartered in Princeton, NJ.